share_log

Regeneron Pharmaceuticals | 8-K: Current report

Regeneron Pharmaceuticals | 8-K: Current report

再生元制药公司 | 8-K:重大事件
美股SEC公告 ·  2024/07/08 04:02

Moomoo AI 已提取核心信息

Regeneron Pharmaceuticals anticipates recording an acquired in-process research and development (IPR&D) charge of approximately $24 million pre-tax for Q2 2024. This charge stems from up-front payments and premium payments on equity securities related to collaboration and licensing agreements.The IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.18 for the second quarter. The company notes that these preliminary results are subject to financial statement closing procedures and actual results may differ from current estimates.
Regeneron Pharmaceuticals anticipates recording an acquired in-process research and development (IPR&D) charge of approximately $24 million pre-tax for Q2 2024. This charge stems from up-front payments and premium payments on equity securities related to collaboration and licensing agreements.The IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.18 for the second quarter. The company notes that these preliminary results are subject to financial statement closing procedures and actual results may differ from current estimates.
再生元制药公司预计在2024年第二季度将为收购的在研研究与开发(IPR&D)计提2400万美元的税前费用。此费用与合作和许可协议相关,预计将使每股稀释后GAAP和非GAAP净利润都减少约0.18美元。IPR&D费用包括预付款和购买股票证券的溢价。再生元指出,因未来发生的事件、规模和时间的不确定性,这类费用无法预测。公司强调,2024年第二季度的结果是初步的,需遵循财务报表的结算程序。再生元还对其非GAAP财务指标进行了说明,指出这些指标排除了GAAP数据中的某些非现金和其他项目。虽然用于计划和运营决策,但公司承认使用这些非GAAP指标的局限性,因为它们排除了经常性费用,可能无法与其他公司的非GAAP信息进行比较。
再生元制药公司预计在2024年第二季度将为收购的在研研究与开发(IPR&D)计提2400万美元的税前费用。此费用与合作和许可协议相关,预计将使每股稀释后GAAP和非GAAP净利润都减少约0.18美元。IPR&D费用包括预付款和购买股票证券的溢价。再生元指出,因未来发生的事件、规模和时间的不确定性,这类费用无法预测。公司强调,2024年第二季度的结果是初步的,需遵循财务报表的结算程序。再生元还对其非GAAP财务指标进行了说明,指出这些指标排除了GAAP数据中的某些非现金和其他项目。虽然用于计划和运营决策,但公司承认使用这些非GAAP指标的局限性,因为它们排除了经常性费用,可能无法与其他公司的非GAAP信息进行比较。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息